Craft distilleries in the US

Novo Nordisk's semaglutide revenue and the number of US craft distilleries have, between 2018 and 2023, risen together at a correlation of 0.967. A Danish weight-loss drug and a small-batch spirits industry scaling at the same rate. An American buying whiskey from a farm in Kentucky and taking a GLP-1 shot on Sunday is, statistically speaking, not an edge case.

Novo Nordisk's Ozempic and Wegovy revenue grew from around $2 billion in 2018 to over $24 billion by 2023 as semaglutide crossed from diabetes management into broad weight-loss prescribing. U.S. craft distilleries grew from around 1,700 in 2018 to over 2,300 by 2023, driven by continued state licensing and the durable consumer preference for local, provenance-rich spirits. Both trends belong to the same upper-middle-class American household — the same household that is now drinking less whiskey per ounce but paying more per bottle, and also, occasionally, on semaglutide.

Six years of two lines rising together can describe a decade paying more for appetite-suppressing medication and better whiskey. Both are ways of managing what the body wants.